



## **aTyr Pharma to Participate in September Investor Conferences**

August 21, 2024

SAN DIEGO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in several upcoming investor conferences scheduled to take place in September 2024.

Details of the conferences appear below:

Conference: Wells Fargo Healthcare Conference

Date: Thursday, September 5, 2024

Location: Everett, MA

Format: 1x1 Investor Meetings

Conference: H.C. Wainwright 26<sup>th</sup> Annual Global Investment Conference

Date: Wednesday, September 11, 2024

Time: 10:30am EDT

Location: New York, NY

Format: Corporate Presentation

Conference: Cantor Fitzgerald Global Healthcare Conference

Date: Wednesday, September 18, 2024

Time: 1:55pm EDT

Location: New York, NY

Format: Corporate Presentation

In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conferences. A webcast of the H.C. Wainwright and Cantor Fitzgerald presentations will be available on the Investor's section of the company's website at [www.atyrpharma.com](http://www.atyrpharma.com). Following the events, a replay of the presentations will be available on the aTyr website for at least 90 days. For more information, contact [investorrelations@atyrpharma.com](mailto:investorrelations@atyrpharma.com).

### **About aTyr**

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr's discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr's lead therapeutic candidate is efzofitmod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit [www.atyrpharma.com](http://www.atyrpharma.com).

### **Contact:**

Ashlee Dunston

Director, Investor Relations and Public Affairs

[adunston@atyrpharma.com](mailto:adunston@atyrpharma.com)

Source: aTyr Pharma, Inc.